United States-based Amgen (NASDAQ: AMGN) has signed a joint initiative with United States-based Direct Relief, it was reported yesterday.
According to the joint initiative, Direct Relief will distribute USD93m worth of Amgen donated cancer treatments and supportive care medicines. This donation will provide cancer patients in 18 developing countries with access to Neulasta (pegfilgrastim), NEUPOGEN (filgrastim) and Vectibix (panitumumab).
Patients will obtain the donated medicines through Direct Relief-partner hospitals and clinics in the following countries, Armenia, Cambodia, Dominican Republic, Ethiopia, Ghana, Haiti, Honduras, India, Jamaica, Malawi, Myanmar, Nepal, Nicaragua, Pakistan, Paraguay, Senegal, Tanzania and Uganda. The first shipments of the nearly 110,000 units of donated medicines have already reached cancer clinics in destination countries and are available to patients. Donated medicines will serve approximately 7,400 low-income patients.
Amgen and Direct Relief said that they will continue to seek opportunities to partner in the future to bring innovative biologics to patients in need.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval